ABT 199(also known as GDC 0199, Venetoclax) is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It is typically used to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
ABT-199: A New Hope for Selective BCL-2 Inhibition.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
 M.S.Davids, et al, Cancer Cell, 2013, 23(2), pp 139-141.
 A.J.Souers, et al, Nat. Med., 2013, 19(2), pp 202-208.
 M.Vogler, et al, Brit. J. Haematol., 2013, 163(1), pp 139-142.
 H.Tamaki, et al, Oncotarget., 2014, 5(22), pp 11399-11412.